{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:12:53Z","timestamp":1790903573799,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Indolent T-cell lymphoma of the gastrointestinal tract (iTCL-GI) is rare, lacking standardized treatments. We report a successful venetoclax treatment in one patient with indolent T-cell lymphoma of the gastrointestinal tract. A 35-year-old male was admitted due to complaints of anemia and hematochezia. He was diagnosed with iTCL-GI according to histopathology and next-generation sequencing (NGS). He received the first cycle of CHOP-E chemotherapy, but he continued to have intermittent blood in stools. After starting oral Bcl-2 inhibitor venetoclax, the results of peripheral hemogram and the body temperature gradually turned normal, with no symptoms of hematochezia occurring again. In addition, colonoscopy showed improved ulcers in the ascending and transverse colon. Routine blood tests returned to normal without adverse effects. Therefore, venetoclax may represent a potential treatment approach for iTCL-GI. This report might provide clues for the future management of similar cases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1593343","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:28:04Z","timestamp":1751347684000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effective venetoclax treatment for indolent T-cell lymphoma of the gastrointestinal tract: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Ji-Mo","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zou-Fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225774","article-title":"Primary gastrointestinal T-cell lymphoma and indolent lymphoproliferative disorders: practical diagnostic and treatment approaches","volume":"13","author":"Nishimura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/1066896918785985","article-title":"Disease progression in a patient with indolent T-cell lymphoproliferative disease of the gastrointestinal tract","volume":"27","author":"Perry","year":"2019","journal-title":"Int J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102028","article-title":"Indolent T-cell\/natural killer-cell lymphomas\/lymphoproliferative disorders of the gastrointestinal tract-what have we learned in the last decade","volume":"104","author":"Wang","year":"2024","journal-title":"Lab Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.10.001","article-title":"T- and nk-cell lymphoproliferative disorders of the gastrointestinal tract: review and update","volume":"52","author":"van Vliet","year":"2020","journal-title":"Pathology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01276","article-title":"Indolent T-cell lymphoproliferative disease of the GI tract: insights for better diagnosis, prognosis, and appropriate therapy","volume":"10","author":"K\u00fc\u00e7\u00fck","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15880","article-title":"Metronomic chemotherapy for indolent T-cell lymphoproliferative disorder of the gastrointestinal tract","volume":"114","author":"Liu","year":"2023","journal-title":"Cancer Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3960\/jslrt.19022","article-title":"Indolent T-cell lymphoproliferative disorder of the stomach successfully treated by radiotherapy","volume":"60","author":"Takahashi","year":"2020","journal-title":"J Clin Exp Hematop"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00539-3","article-title":"Venetoclax for the treatment of chronic lymphocytic leukemia","volume":"14","author":"Eradat","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016685803","article-title":"Venetoclax: A first-in-class oral bcl-2 inhibitor for the management of lymphoid Malignancies","volume":"51","author":"King","year":"2017","journal-title":"Ann Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41408-022-00756-9","article-title":"Chronic lymphocytic leukemia treatment algorithm 2022","volume":"12","author":"Hampel","year":"2022","journal-title":"Blood Cancer J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1182\/blood-2023-187128","article-title":"Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03467-5","article-title":"Indolent T-cell lymphoproliferative disorder of gastrointestinal tract with unusual clinical courses: report of 6 cases and literature review","volume":"482","author":"Fan","year":"2023","journal-title":"Virchows Arch"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512830","article-title":"Indolent T-cell lymphoproliferative disease of the gastrointestinal tract","volume":"122","author":"Perry","year":"2013","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13172767","article-title":"Endoscopic and histopathological characteristics of gastrointestinal lymphoma: A multicentric study","volume":"13","author":"Tran","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106336","article-title":"Peripheral T-cell lymphoma with gastrointestinal involvement and indolent T-lymphoproliferative disorders of the gastrointestinal tract","volume":"91","author":"Kohri","year":"2020","journal-title":"Leuk Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-20-54","article-title":"Indolent T cell lymphoproliferative disorder of the gastrointestinal tract: an uncommon case with lymph node involvement and the classic hodgkin's lymphoma","volume":"11","author":"Wu","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230961","article-title":"Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract","volume":"105","author":"Soderquist","year":"2020","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0529-5807.2019.10.003","article-title":"Clinicopathological features of indolent T-cell lymphoproliferative disorder of the gastrointestinal tract: A report of five cases","volume":"48","author":"Shao","year":"2019","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02704-8","article-title":"Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas","volume":"476","author":"Montes-Moreno","year":"2020","journal-title":"Virchows Arch"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-830968","article-title":"Recurrent stat3-jak2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract","volume":"131","author":"Sharma","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0678-3","article-title":"Targetability of stat3-jak2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract","volume":"34","author":"Hu","year":"2020","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S189825","article-title":"Comparison of chop vs chope for treatment of peripheral T-cell lymphoma: A meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4103\/crst.crst_179_22","article-title":"Venetoclax: A narrative drug review","volume":"5","author":"Rajendra","year":"2022","journal-title":"Cancer Research Statistics Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel bcl-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225608","article-title":"Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance","volume":"13","author":"Garciaz","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1593343\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:28:05Z","timestamp":1751347685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1593343\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1593343"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1593343","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"1593343"}}